Thought I might post this in case anyone else is interested,...

Thought I might post this in case anyone else is interested, seeing as there hasn't been much news of late.

https://www.linkedin.com/pulse/we-say-goodbye-2015-hello-2016-sean-hall

We say goodbye to 2015 and hello to 2016

Dear All,
What an amazing year, I wanted to thank our supporters and share a few highlights.
This year saw a number of pivotal outcomes that shaped Medlab:

1. We floated to the Australian Stock Exchange within 3 years of starting research operations, ASX: MDC.
2. We were lawfully granted a research licence to develop new medicines from cannabis here in Australia.
3. We developed 2 probiotic strains bonded to an amino acid that biochemically activate the production of lean body mass in the human body.
4. We showed in animal studies that several specifically selected probiotics in the right combination can rescue non alcoholic fatty liver disease (NAFLD).
5. We engineered a remarkable small particle absorption platform called NanoCelle for drug delivery that is unique in every way.
6. We developed prototypes for safer more effective statins, insulin and testosterone.
7. Our human research into medication resistant Depressed patients shows we can improve patient models using a unique blend of probiotics and minerals beyond that of an SSRI.
8. Nutraceutical commercialisation is well underway with global interest.

In 2016, our human trial agenda increases, as well as our expansion of the nutraceutical business.
Medalb's aim is simple, expand the practitioner's toolbox to offer greater therapeutic choice when treating or managing patients with chronic diseases.
A special heart-felt thank you to our supporters. Stay safe these holidays, and see you in the New Year.
Respectfully,
Sean Hall
CEO, Medlab Clinical LTD